azathioprine / Generic mfg. - LARVOL DELTA

Assessment of thiopurine S-methyltransferase allele frequencies and phenotype-genotype concordance in a Tunisian population. (PubMed, Drug Metab Pers Ther) - "Overall, 12.5 % of the Tunisian subjects were found to carry the TPMT *3C allele. However, detecting novel and rare TPMT alleles within a larger cohort essential for more accurate estimation of genotype-phenotype correlation in our population. Combining genotyping and phenotyping is likely represents the most effective approach to prevent life-threatening myelosuppression associated with thiopurines."

Journal • TPMT

SCHEDULES AND SURVIVAL OF RITUXIMAB IN PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY ASSOCIATED VASCULITIS: A MULTI-CENTER, REAL-WORLD EXPERIENCE (EULAR 2025) - "Rituximab (RTX), a monoclonal antibody targeting CD20-positive B cells, has revolutionized the management of AAV by offering an alternative to cyclophosphamide (CYC) and reducing reliance on prolonged glucocorticoid therapy...Renal AAV patients were more likely to receive combination therapy with CYC during induction (p = 0.026), while non-renal AAV patients more frequently received methotrexate (MTX) or azathioprine (AZA) during maintenance due to renal contraindications... This study highlights the efficacy and safety of RTX as a cornerstone therapy for AAV in real-world settings. The comparable remission rates observed in RI and non-RI subgroups emphasize RTX’s broad applicability across diverse disease phenotypes. While RI influenced treatment regimens, it did not significantly impact drug retention or long-term outcomes, underscoring RTX’s robustness in managing even severe cases and use in combination with CYC in selected cases."

Clinical • Real-world • Real-world evidence • ANCA Vasculitis • Eosinophilic Granulomatosis With Polyangiitis • Glomerulonephritis • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Lupus Nephritis • Nephrology • Rare Diseases • Vasculitis

EFFICACY OF AVACOPAN AS INDUCTION THERAPY IN ANCA-ASSOCIATED VASCULITIS: A JAPANESE MULTICENTER COHORT STUDY (J-CANVAS STUDY) (EULAR 2025) - " This study utilized data from the Japanese AAV patient registry (J-CANVAS), specifically focusing on cases of newly diagnosed or severely relapsed microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) registered between January 2017 and March 2023, who received intravenous cyclophosphamide (IVCY) or rituximab (RTX) as induction therapy...Azathioprine was the most commonly used concomitant medication in both groups during remission maintenance, at 26.4% in the Avacopan group and 44.2% in the control group (p=0.16)... In Japan, Avacopan is primarily utilized for AAV patients with severe renal dysfunction, demonstrating comparable remission rates to conventional therapy. On the other hand, renal dysfunction remained over the 48-week observation period after remission induction, regardless of whether Avacopan was used or not. Notably, it enabled a significant and earlier reduction in PSL use, potentially mitigating long-term glucocorticoid-related adverse..."

Clinical • ANCA Vasculitis • Infectious Disease • Inflammation • Nephrology • Pain • Rare Diseases • Renal Disease • Vasculitis

EVALUATION OF THE PROGNOSTIC EFFECT OF ADDING DISEASE MODIFYING ANTI-RHEUMATISMAL DRUGS TO GLUCOCORTICOIDS IN THE TREATMENT OF POLYMYALGIA RHEUMATICA (EULAR 2025) - "All patients received prednisone or an equivalent GC as the initial treatment, with a median dose of 15 (15-20) mg and a median treatment duration of 20 (11-35.5) months...During follow-up, 99 (63%) patients received DMARDs in addition to GC, including methotrexate (69 patients, 69.6%), leflunomide (27 patients, 27.2%), hydroxychloroquine (11 patients, 11.1%), azathioprine (4 patients, 4.04%), and tocilizumab (3 patients, 3.03%)... In our retrospective study, the addition of DMARDs to GC therapy in PMR patients did not significantly affect the duration of GC use or relapse rates. However, the potential benefits and risks of DMARD use should be further investigated in future studies. Baseline characteristics of patients"

Cardiovascular • Cataract • Diabetes • Giant Cell Arteritis • Hematological Disorders • Herpes Zoster • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Musculoskeletal Pain • Ophthalmology • Osteoporosis • Pain • Rheumatology • Varicella Zoster

TREATMENT PREFERENCES IN EARLY SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: REAL-WORLD DATA FROM THE TURKISH SYSTEMIC SCLEROSIS REGISTRY (EULAR 2025) - "Current treatment guidelines also emphasize the role of antifibrotic agents, such as nintedanib, as an option for slowing the progression of fibrotic changes in the lungs...Among the conventional immunosuppressives, mycophenolate mofetil (MMF) was the most frequently preferred agent (69.6%), followed by cyclophosphamide (CYC) (13,7%) and azathioprine (AZA) (3.9%)... Real-world data from our registry revealed that mycophenolate mofetil (MMF) was the most commonly preferred conventional immunosuppressive for early-stage SSc-ILD, aligning with current guidelines and consistent with previous reports [1]. However, the proportion of patients receiving antifibrotic therapy was lower in our registry, which may be attributed to the short disease duration. Long-term follow-up with comparative analyses of treatment responses would provide more valuable insights."

Clinical • Real-world • Real-world evidence • Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis

TREATMENT WITH HYDROXYCHLOROQUINE IS ASSOCIATED WITH IMPROVED SURVIVAL IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (EULAR 2025) - "The immunosuppressive agents were mycophenolate mofetil (13 patients), azathioprine (7), methotrexate (7), cyclophosphamide (5), hydroxychloroquine (9), prednisolone (4) rituximab (1) and tocilizumab (1). Our findings suggest that immunosuppression may improve survival in SSc-PAH, an outcome mainly driven by the effect of hydroxychloroquine. This is consistent with the plausible protective endothelial effect of hydroxychloroquine on vasculopathy. Considering the limitations of a retrospective approach, future prospective studies are warranted."

Cardiovascular • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

A REAL-WORLD PERSPECTIVE ON THE ASSOCIATION OF IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE OUTCOMES AND DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2025) - "Most patients received hydroxychloroquine (83%), with mycophenolate mofetil (49.4%) being the most commonly prescribed immunosuppressant, followed by azathioprine (44.9%). In patients with active SLE, clinically important improvements in disease activity were particularly notable among those who reported clinically meaningful improvements in MCS scores, physical function, and mental health domains of the SF-36 at one year. Patients demonstrating meaningful improvements in both MCS and PCS scores also experienced greater reductions in SLEDAI-2K scores at one year. PCS and MCS score responders consistently showed lower SLEDAI-2K values over five years as compared to non-responders."

Clinical • HEOR • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Musculoskeletal Diseases • Pain • Systemic Lupus Erythematosus

ANIFROLUMAB IN CUTANEOUS AND SYSTEMIC LUPUS ERYTHEMATOSUS: A REAL-LIFE EXPERIENCE (EULAR 2025) - "All patients had previously received prednisone and antimalarials, in addition to an average of 2.8 immunosuppressant/biologic drugs: azathioprine (n=6), methotrexate (n=7), mycophenolate (n=8), rituximab (n=3), or belimumab (n=9). Our findings suggest that anifrolumab is broadly effective in reducing SLE and CLE disease activity across various patient demographics and CLE subtypes. Type-I IFN signature could be a potential biomarker for monitoring clinical response to treatment."

Clinical • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Oncology • Pain • Pulmonary Disease • Respiratory Diseases • Systemic Lupus Erythematosus • Varicella Zoster

MONOGENIC LUPUS: A COMPREHENSIVE REVIEW OF GENETIC AND CLINICAL FEATURES (EULAR 2025) - "Additionally, patients with MSK involvement had higher rates of azathioprine (AZA) and intravenous immunoglobulin (IVIG) use (%60.5 vs %28.6 p-value:0.019, %53.3 vs %18.8 p-value:0.031)...Furthermore, methotrexate (MTX), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) were used more frequently in these patients (%50 vs %15.6 p-value:0.027, %80.9 vs %45.9 p-value:0.001, %65.7 vs %17.5 p-value:0.000)... Genes involved in nucleic acid clearance, complement activation, and immune tolerance regulation were the most frequently affected among these patients. Lung, heart, hematological, and neurological involvement, and unresponsiveness to GCs were associated with mortality. Patients exhibiting these features should be closely monitored and treated more aggressively."

Clinical • Review • Immunology • Inflammatory Arthritis • Lupus • Musculoskeletal Diseases

DIFFERENTIAL EFFICACY OF INDUCTION TREATMENTS FOR LUPUS NEPHRITIS AT ONSET AND RELAPSES: AN OBSERVATIONAL STUDY (EULAR 2025) - "According to current international guidelines [2, 3], mycophenolate mofetil (MMF) and cyclophosphamide (CYC) are the agents of choice for the induction treatment of new-onset LN, with alternatives including Rituximab (RTX) or calcineurin inhibitors (CNI) such as tacrolimus or cyclosporine...Other patients received azathioprine or steroid therapy only... MMF and CYC are most effective to induce remission at LN onset and relapse, with MMF showing lower FL rates at relapse. However, patients on CYC had a rather high number of flares. CNI are also associated with low FL rate at LN relapse."

Clinical • Observational data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus

RELATIONSHIP BETWEEN ACHIEVEMENT OF LLDAS AFTER REMISSION INDUCTION THERAPY AND LONG-TERM PROGNOSIS AT 7 YEARS IN SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2025) - "During remission induction therapy, the average starting dosage of prednisolone (PSL) was 50.7 mg/day, with 58.3% receiving cyclophosphamide, 25.0% mycophenolate mofetil (MMF), and 13.9% calcineurin inhibitors (CNI). The subsequent therapies included MMF (53.7%), azathioprine (39.0%), CNI (36.6%), and biological agents (2.4%)... Achieving LLDAS within 12 months after starting remission induction therapy in SLE patients is associated with higher DORIS remission rates at 7 years, particularly among those who remain flare-free during follow-up. Severe flares after achieving LLDAS may contribute to an increased risk of long-term damage accrual, suggesting the importance of optimal maintenance therapy, as well as induction therapy."

Clinical • Immunology • Inflammatory Arthritis • Lupus • Rheumatology • Systemic Lupus Erythematosus

CONSENSUS-BASED RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A DELPHI STUDY IN THE GULF REGION (EULAR 2025) - "General therapeutic strategies include TPMT testing before initiating azathioprine, the unnecessity of G6PD testing before starting hydroxychloroquine, indications for repeat renal biopsy, and the need for caution with aesthetic treatments and cosmetic procedures. We present the first comprehensive set of overarching principles and recommendations specific to the Gulf region on the management of SLE. These were based on an elaborate systematic literature review, integrating clinical evidence and regional expertise."

Aesthetic Medicine • Cutaneous Lupus Erythematosus • Fatigue • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Obstetrics • Psychiatry • Rheumatology • Systemic Lupus Erythematosus

MEDICATION ADHERENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS: INSIGHTS FROM A KENYAN SLE COHORT (KESLER) (EULAR 2025) - "The most prescribed medications were hydroxychloroquine (84.5%) and prednisone (53.4%), followed by azathioprine (32.8%) and mycophenolate mofetil (25.9%). Less frequently used medications included methotrexate (5.2%), rituximab (6.9%), and cyclophosphamide (3.4%)... We have identified significant barriers to medication adherence in LMIC settings. Lower adherence was multifactorial and highlights the need for comprehensive interventions, including financial support and patient education, to address both economic and behavioural barriers to medication adherence. It will be essential to incorporate these socioeconomic factors into the design of interventions aimed at improving healthcare access and promoting equity in the Global South."

Adherence • Cognitive Disorders • Fatigue • Immunology • Inflammatory Arthritis • Lupus • Rheumatology • Systemic Lupus Erythematosus

INCIDENCE AND RISK FACTORS OF HERPES ZOSTER INFECTION IN PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS: A 16 YEAR STUDY (EULAR 2025) - "The median Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) at herpes zoster diagnosis was 4 (IQR = 0 – 12), 16.39% had recurrent HZI, 11.48% had superimposed bacterial infection, and more than two-thirds were treated with the anti-viral acyclovir or valacyclovir (88.52%). The prevalence and incidence of HZI in cSLE is 15.72% and 38.40 per 100 person-years, respectively. Risk factors identified for HZI among cSLE were lymphopenia, lupus nephritis, and immunosuppressive agents. In particular, IV cyclophosphamide, azathioprine, and glucocorticoid dose of ≥5mg increased the risk for development of HZI by 1.61, 2.07, 10.20 times, respectively."

Clinical • Glomerulonephritis • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pediatrics • Rheumatology • Systemic Lupus Erythematosus • Varicella Zoster

CLUSTER ANALYSIS OF AUTOANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2025) - "Besides, they had a higher frequency of osteoporosis (11.0%) and severe infections (26.4%) and a higher use of glucocorticoids (93.5%), azathioprine (42.0%), cyclophosphamide (25.5%) and mycophenolate mofetil (24.0%). In our cohort, the serological profile constitutes a crucial factor for the clinical stratification of patients and predicting their prognosis. Nevertheless, further studies are required to facilitate a more precise identification and comprehensive understanding of these patients."

Clinical • Anemia • Cardiovascular • Glomerulonephritis • Hematological Disorders • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Leukopenia • Lupus • Lupus Nephritis • Myositis • Nephrology • Osteoporosis • Rheumatology • Systemic Lupus Erythematosus • Thrombocytopenia • Vasculitis

REGISTRY OF ANIFROLUMAB USE IN SYSTEMIC LUPUS ERYTHEMATOSUS IN THE VALENCIAN COMMUNITY (EULAR 2025) - "Only 1 patient was treated with anifrolumab without prior disease-modifying antirheumatic drugs (DMARDs) therapy, with an average of 2.6±1.25 previous DMARDs (23 hydroxychloroquine, 13 MTX, 15 azathioprine, 10 mycophenolate, 5 tacrolimus, 5 leflunomide, 1 cyclosporine, 1 chloroquine, 1 dapsone). The mean number of prior biologics before starting Anifrolumab was 1.29±0.78 (15 belimumab, 13 rituximab, 1 tocilizumab, 1 abatacept, 2 antiTNF, 1 cenerimod). Only 33.33% required corticosteroid boluses, and one required cyclophosphamide. Anifrolumab was concomitantly prescribed with hydroxychloroquine in 53.33% of patients, mycophenolate in 13.33%, methotrexate in 20% and azathioprine, tacrolimus and mepacrine in 6.66%... From the third month of Anifrolumab treatment, a significant reduction in prednisone dose mantained until 6th month, as well as SLEDAI scores, were observed. The domains showing the greatest improvement were hematological, joint, and mucocutaneous,..."

Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

SYSTEMIC LUPUS ERYTHEMATOSUS IN GHANA: DESCRIPTION OF AN INCEPTION COHORT AND TIME TREND ANALYSIS (EULAR 2025) - "Steroids and hydroxychloroquine were prescribed in 95.0% and 87.7% of patients, respectively. Disease-modifying anti-rheumatic drugs such as azathioprine and methotrexate were frequently used, while the use of biological agents remained scarce... This study enhances the understanding of SLE in Ghana, revealing similarities and distinctions with global cohorts. It underscores the critical need for African regional lupus registries to improve patient outcomes through tailored healthcare strategies. Clinical features at first presentation"

CNS Disorders • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Musculoskeletal Diseases • Nephrology • Pediatrics • Psychiatry • Renal Disease • Rheumatology • Systemic Lupus Erythematosus • CRP

UNRAVELING THE DIVERSE TREATMENT LANDSCAPE FOR PATIENTS WITH INTERSTITIAL LUNG DISEASE IN SJÖGREN'S DISEASE (EULAR 2025) - "Glucocorticoids (GC) (39.3%) were the most frequently prescribed treatment, followed by rituximab (RTX) (16.0%), azathioprine (AZA) (12.9%), and mycophenolate mofetil (MMF) (10.4%) (Figure 1A). Monotherapy with a single DMARD was seen in 16.0%, while 9.2% received combination therapy, primarily MMF or methotrexate with RTX. When assessing the used therapies segregated by ILD pattern, Nintedanib use was observed in UIP patients (20%), while rituximab was more frequent in cases classified as other patterns, such as bronchiolitis (44%) (Figure 1B). This study highlights the variability in treatment patterns for SjD-ILD, emphasizing the importance of studies assessing treatment efficacy in SjD-ILD. Our findings underscore the need for standardized treatment protocols and further research to refine and optimize management strategies for SjD-ILD.#."

Clinical • Infectious Disease • Interstitial Lung Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Sjogren's Syndrome

SJÖGREN'S SYNDROME: A DIFFICULT ENTITY TO DIAGNOSE IN PEDIATRIC AGE (EULAR 2025) - "As in the literature, in our series the most frequent symptomatology at the beginning was musculoskeletal (67%). Recurrent parotitis has also been described as a distinctive manifestation in children, showing an inverse relationship between the age of onset and the incidence of parotitis. Clinical manifestations were varied, highlighting renal involvement in 3 patients."

Clinical • Cardiovascular • Dental Disorders • Dry Eye Disease • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Lupus • Mumps • Musculoskeletal Diseases • Ophthalmology • Otorhinolaryngology • Pediatrics • Rheumatology • Sjogren's Syndrome • Systemic Lupus Erythematosus • Xerostomia

INTERSTITIAL LUNG DISEASE IN PRIMARY SJÖGREN SYNDROME: PATHOCHRONY, SERONEGATIVE CASES, AND RISK OF PROGRESSIVE PULMONARY FIBROSIS (EULAR 2025) - "Treatments included glucocorticoids in 77% of patients (33/43; mean initial dose of prednisone: 32 ± 14 mg/day), immunosuppressants in 77% (33/43; mycophenolate in 31 and azathioprine in 2), and biologic agents in 28% (12/43; rituximab in 11 and abatacept in 1). Antifibrotic agents (nintedanib or pirfenidone) were added in 26% (10/43) of patients due to progression to progressive pulmonary fibrosis (PPF)... In 78% of our cases, ILD was either the presenting symptom or the predominant manifestation that led to the diagnosis of pSS. This condition should be considered in patients with ILD and sicca syndrome, even in the absence of characteristic antibodies, as 38% of our cases were seronegative. At least 26% of patients progressed to PPF, requiring antifibrotic treatment."

Clinical • Fibrosis • Immunology • Infectious Disease • Interstitial Lung Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Rheumatology • Sjogren's Syndrome

URINARY T-HELPER CELLS ARE A POTENTIAL BIOMARKER FOR TUBULOINTERSTITIAL NEPHRITIS IN SJÖGREN'S SYNDROME (EULAR 2025) - "Patients with SJS-TIN were treated with a range of drugs (Prednisolone, Azathioprine, Rituximab) as per discretion of the treating clinician. Our prospective proof-of-principle study shows that quantification and differentiation of urinary leukocytes is possible and can be used for clinical routine. Among urinary leukocytes, particularly T H cells correlate with presence and severity of SJS-TIN at diagnosis and reflect response to therapy. Thus, urinary T H cells might represent the first reported non-invasive biomarker for SJS-TIN."

Biomarker • Chronic Kidney Disease • Immunology • Infectious Disease • Inflammation • Nephrology • Renal Disease • Sjogren's Syndrome • CD4 • CD8

TREATMENT PATTERNS AND DETERMINANTS OF DMARD SWITCHING IN EUROPEAN RHEUMATOID ARTHRITIS COHORTS: A MULTI-NATIONAL ANALYSIS (EULAR 2025) - "The type of DMARD initiated was categorised as MTX, other conventional synthetic DMARD (csDMARD: hydroxychloroquine, sulfasalazine, leflunomide, cyclosporine, azathioprine), tumor necrosis factor inhibitors (TNFi: adalimumab, infliximab, etanercept, certolizumab pegol, golimumab), non-TNFi (abatacept, anakinra, rituximab, tocilizumab, sarilumab), and Janus Kinase inhibitors (JAKi: tofacitinib, baricitinib, upadacitib, filgotinib). Despite similar treatment guidelines within the Europe countries, there are clear differences in the use and sequencing of DMARDs in newly diagnosed RA, particularly for second-line DMARDs. Further analyses are needed to understand how these differences affect remission rates and other treatment outcomes in RA."

Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

THE IMPACT OF CONVENTIONAL SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS ON THE NEUTROPHIL-LYMPHOCYTE RATIO IN PSORIATIC ARTHRITIS PATIENTS (EULAR 2025) - "The NLR of patients was calculated pre- and at least 6 months post-initiation of csDMARDs – the majority of which having monotherapy with methotrexate or combination DMARD therapy of either methotrexate and/or sulfasalazine with other csDMARDs (leflunomide, ciclosporin, apremilast, azathioprine, and/or hydroxychloroquine). Whilst the data collected is consistent with current literature noting that both methotrexate monotherapy and combination therapies of csDMARDs in other rheumatic conditions pose increases in NLRs, the data was not of statistical significance."

Clinical • Cardiovascular • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

UVEITIS IN RHEUMATIC DISEASES- DATA FROM A ROMANIAN TERTIARY CENTER (EULAR 2025) - "Distribution of biological therapies were as follows: Adalimumab (ADA) – 16 (51.61%), Etanercept (ETA) - 5 (16.13%), Infliximab (INF) - 4 (12.9%), Certolizumab (CZP) – 2(6.45%), Secukinumab (SEK) – 1 (3.23%), Golimumab (GOL) – 1(3.23%), Guselkumab (GUS) – 1(3.23%) and Upadacitinib (UPA) – 1(3.23%)...Pertaining to conventional immunosupressives, 40.35% of the patients included in the study were taking csDMARDs, with the following distribtuion: Methotrexate – 12 (21,05%), Sulfasalazine – 5 (8.77%), Leflunomide – 2 (3.51%), Azathioprine – 2 (3.51%), Mycophenolate mofetil – 1(1.75%) and 2 (3.51%) patients with a combination of Azathioprine and Hydroxychloroquine... Our study revealed that spondyloarthritis was the most common rheumatic disease associated with uveitis, with the majority of cases being unilateral and anterior. Women were significantly more likely than men to experience uveitis episodes. Additionally, some patients required changes in biological therapy due to..."

ANCA Vasculitis • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Lupus • Ocular Inflammation • Ophthalmology • Psoriatic Arthritis • Rare Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Sjogren's Syndrome • Spondylarthritis • Systemic Lupus Erythematosus • Uveitis • Vasculitis

ANALYSIS OF THE DIAGNOSTIC-THERAPEUTIC APPROACH IN PATIENTS WITH DIFUSSE INTERSTICIAL LUNG DISEASES BY A MULTIDISCIPLINARY COMITTEE ON SYSTEMIS AUTOINMUNE RHEUMATIC DISEASES IN S TERTIARY HODPITAL (EULAR 2025) - "Prior to evaluation by the committee, 48% (n=24) patients were on treatment with synthetic DMARDs, followed as 28% (n=14) with immunosuppressants (such as mycophenolate or azathioprine), and to biological therapy in 24% (n=12)...Furthermore, the incidence of glucocorticoid use was lower after expert decision (50% vs. 72%), primarily involving low-dose corticosteroids (defined as ≤ 10 mg/day of prednisone or its equivalent)... Multidisciplinary committees play a pivotal role in the management of interstitial lung disease (ILD), providing a comprehensive approach to diagnosis, treatment, and ongoing patient management. The collaborative environment promotes more diagnostic accuracy, personalized treatment strategies, and improved patient outcomes. Given the complexity and heterogeneous nature of ILD, it is crucial for healthcare institutions to prioritize the implementation of multidisciplinary teams, as thesy significantly contribute to the effectiveness of clinical..."

Clinical • Fibrosis • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Myositis • Pneumonia • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis